topotecan has been researched along with Epithelial Ovarian Cancer in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 20 (80.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, CH; Joung, JG; Kim, BG; Kim, HS; Kim, JW; Kim, S; Lee, JB; Lee, JY; Park, E | 1 |
| Januchowski, R; Jopek, K; Kaźmierczak, D; Nowicki, M; Rucinski, M; Stasiak, P | 1 |
| Arndt, T; Belau, AK; Braicu, EI; Canzler, U; Chekerov, R; de Gregorio, N; Mahner, S; Mustea, A; Neunhoeffer, T; Pietzner, K; Richter, R; Sehouli, J; Stocker, G; Strauß, HG; von Abel, E; Wimberger, P; Woelber, L; Yalinkaya, I | 1 |
| Bastière-Truchot, L; Berger, R; Berton-Rigaud, D; Cardona, A; Colombo, N; du Bois, A; González Martin, A; Greimel, E; Grischke, EM; Hilpert, F; Kroep, JR; Kurzeder, C; Lorusso, D; Lück, HJ; Martinez-Garcia, J; Mirza, MR; Ottevanger, P; Pardo, B; Rau, J; Redondo, A; Selle, F; Vergote, I | 1 |
| Bergamini, A; Bocciolone, L; Candiani, M; Fodor, A; Mangili, G | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Murai, J | 1 |
| Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T | 1 |
| Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD | 1 |
| Kim, JC; Kim, JH; Kim, YM; Yoon, YS | 1 |
| Fekete, JT; Győrffy, B; Menyhárt, O | 1 |
| Braicu, EI; Canaz, E; Chekerov, R; Grabowski, JP; Richter, R; Sehouli, J | 1 |
| Alavi, S; Chekerov, R; Inci, G; Richter, R; Sehouli, J; Woopen, H | 1 |
| Blank, SV; Curtin, J; Guddati, AK; Hochster, HS; Ivy, P; Joseph, B; Levinson, B; Muggia, F; Pothuri, B; Shapira, I; Stein, SM; Tiersten, A | 1 |
| Barron, R; Chandler, DB; Fust, K; Li, X; Lyman, GH; Maschio, M; Parthan, A; Walli-Attaei, M; Weinstein, MC | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Chang Chien, CC; Fu, HC; Hu, CF; Lin, H; Ou, YC; Tsai, CC; Wu, CH | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Annunziata, CM; James, J; Kim, MK | 1 |
| Du, XL; Li, L; Shan, CP; Sheng, XG; Wei, P; Zhang, ZH | 1 |
| Anttila, M; Breda, E; Hanker, LC; Husain, A; Ojeda, B; Pujade-Lauraine, E; Vuylsteke, P; Wang, Y | 1 |
| DeBernardo, RL; DeGeest, K; Herzog, TJ; Lentz, SS; Mutch, D; O'Malley, D; Shahin, M; Sill, MW; Walker, JL; Weiner, SA | 1 |
| Amin, MS; Eisenhauer, EA; Hoskins, PJ; Islam, S; O'Brien, AM; Pelletier, LB; Squire, JA; Tu, D; Weberpals, JI | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
| Kitao, A; Matsumoto, K | 1 |
4 review(s) available for topotecan and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option.
Topics: Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Randomized Controlled Trials as Topic; Topotecan | 2019 |
Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Cell Cycle; Cisplatin; DNA Damage; DNA Repair; DNA Replication; DNA-Binding Proteins; Female; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Topotecan | 2017 |
The prognostic and predictive role of pain before systemic chemotherapy in recurrent ovarian cancer: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Pain; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Predictive Value of Tests; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Topotecan | 2020 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
9 trial(s) available for topotecan and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan | 2022 |
Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Leukopenia; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Topotecan | 2023 |
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-3; RNA, Messenger; Topotecan | 2019 |
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan | 2018 |
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Infusion Pumps; Middle Aged; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Survival Analysis; Topotecan | 2013 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan | 2016 |
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).
Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2011 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
12 other study(ies) available for topotecan and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines.
Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Doxorubicin; Female; Humans; MicroRNAs; Ovarian Neoplasms; Topotecan | 2022 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan | 2017 |
Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Republic of Korea; Topotecan | 2019 |
Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan.
Topics: Area Under Curve; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Signal Transduction; Topotecan; Transcriptome; Up-Regulation | 2019 |
Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Young Adult | 2019 |
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Taxoids; Topotecan | 2014 |
The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2015 |
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodiazepinones; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cisplatin; DNA Damage; DNA Repair; Drug Synergism; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinases; Pyrazoles; Topoisomerase I Inhibitors; Topotecan | 2015 |
Clinical observational study of conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Topotecan; Treatment Outcome | 2015 |
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan | 2011 |
[Treatment of recurrent ovarian cancer].
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Reoperation; Topotecan | 2012 |